Multiple mechanisms of dysregulation of receptor tyrosine kinases (RTKs) are observed in human cancers. In addition to gain-of-function, loss of negative regulation also contributes to oncogenic activation of RTKs. Negative regulation of many RTKs involves their internalization and degradation in the lysosome, a process regulated through ubiquitination. RTK oncoproteins activated following chromosomal translocation, are no longer transmembrane proteins, and are predicted to escape lysosomal degradation. To test this, we used the Tpr-Met oncogene, generated following chromosomal translocation of the hepatocyte growth factor receptor (Met). Unlike Met, Tpr-Met is localized in the cytoplasm and also lacks the binding site for Cbl ubiquitin ligases. We determined whether subcellular localization of Tpr-Met, and/or loss of its Cbl-binding site, is important for oncogenic activity. Presence of a Cbl-binding site and ubiquitination of cytosolic Tpr-Met oncoproteins does not alter their transforming activity. In contrast, plasma membrane targeting allows Tpr-Met to enter the endocytic pathway, and Tpr-Met transforming activity as well as protein stability are decreased in a Cbl-dependent manner. We show that transformation by Tpr-Met is in part dependent on its ability to escape normal downregulatory mechanisms. This provides a paradigm for many RTK oncoproteins activated following chromosomal translocation.
Introduction
In normal cells, receptor tyrosine kinase (RTK) activation is tightly regulated. Their inappropriate activation is associated with development and progression of many human malignancies. Multiple mechanisms that deregulate RTKs, involving amplification, chromosomal translocation and mutations, have been identified (Rodrigues and Park, 1994; Blume-Jensen and Hunter, 2001; Lamorte and Park, 2001) . These gain-of-function mechanisms can result in ligand-independent activation or enhanced catalytic activity of RTKs in response to ligand, with increased activation of downstream effectors promoting tumorigenesis. However, in addition to these positive mechanisms, there is growing evidence that escape from negative regulatory mechanisms is an important event in the deregulation of RTKs (Peschard and Park, 2003; Bache et al., 2004) .
In the absence of ligand, most RTKs are catalytically inactive. Binding of ligand promotes receptor dimerization/oligomerization and induces a conformational change that triggers receptor catalytic activity. RTK activation promotes their internalization into the endocytic trafficking pathway, and subsequently, many RTKs are downregulated through lysosomal degradation. Recent publications have established that ubiquitination plays an important role in receptor downregulation (Shtiegman and Yarden, 2003) .
Protein ubiquitination is mediated by an enzymatic cascade composed of an ubiquitin-activating enzyme (E1), an ubiquitin-conjugating enzyme (E2) and a ubiquitin-protein ligase (E3). The presence of a polyubiquitin chain on many cytosolic and nuclear proteins targets them for degradation by the proteasome. In contrast, ubiquitination of many cell-surface receptors correlates with their internalization and lysosomal degradation. Evidence supports that RTKs are multimonoubiquitinated as well as polyubiquitinated (Haglund et al., 2003; Mosesson et al., 2003; Carter et al., 2004; Huang et al., 2006) .
Ubiquitin moieties can constitute binding sites for proteins that contain ubiquitin-binding domains such as ubiquitin-interaction motif (UIM), ubiquitin-associated (UBA) domains and others. UIM-containing proteins, HRS and STAM, are thought to recruit ubiquitinated RTKs to specialized microdomains of sorting endosomes, characterized by a bilayered clathrin coat (Urbe et al., 2003) . These domains internalize and later mature into multivesicular bodies (MVBs) trapping RTKs within internal vesicles. Fusion of MVBs with lysosomes leads to degradation of internal vesicles and their contents. Notably, EGF and Met RTK mutants that are not ubiquitinated are inefficiently sorted in the bilayered clathrin coat and escape lysosomal degradation (Peschard et al., 2001; Katzmann et al., 2002; Waterman et al., 2002; Haglund et al., 2003; Grovdal et al., 2004; Abella et al., 2005) .
The Cbl family of ubiquitin-protein ligases (c-Cbl, Cbl-b and Cbl-3) plays an important role in the liganddependent ubiquitination of many RTKs (Thien and Langdon, 2005) . Several receptors including EGFR, PDGFR, CSF-1R and Met (HGFR) are ubiquitinated following recruitment of c-Cbl (Levkowitz et al., 1998; Miyake et al., 1998; Lee et al., 1999; Peschard et al., 2001 Peschard et al., , 2004 . Cbl ubiquitin-protein ligases are modular proteins that contain a conserved N-terminal tyrosine kinase binding (TKB) domain and a RING-finger domain, in addition to other protein interaction motifs (Thien and Langdon, 2005) . Where tested, the TKB domain interacts with specific phosphotyrosine residues on RTKs, and on cytoplasmic protein tyrosine kinases (PTKs). The RING-finger domain recruits the E2 ubiquitin-conjugating enzyme, UbcH7. Both domains are required for transfer of ubiquitin residues to RTKs and PTKs (Waterman et al., 1999; Thien and Langdon, 2005) . The Met receptor is negatively regulated by internalization and Met degradation is enhanced by recruitment of c-Cbl and Cbl-b (Peschard et al., 2001 (Peschard et al., , 2004 Abella et al., 2005) . The c-Cbl-TKB domain binds to a juxtamembrane tyrosine (1003) residue on Met, and this interaction is essential for Met ubiquitination and degradation (Peschard et al., 2001 ).
An oncogenic form of the Met receptor, Tpr-Met, was generated following a carcinogen-induced chromosomal rearrangement that fused a protein dimerization domain (Tpr) to the kinase domain of the Met receptor (Park et al., 1986) . This results in the deletion of the juxtamembrane tyrosine-binding site for c-Cbl (Y1003), as well as deletion of the extracellular domain of the receptor, rendering the Tpr-Met oncoprotein cytoplasmic. Tpr-Met is constitutively activated, but fails to bind c-Cbl and is not ubiquitinated (Peschard et al., 2001) . Notably, a Met receptor mutant that lacks only the c-Cbl TKB domain-binding site (Y1003F), has a prolonged half-life and is oncogenic in cell culture and tumorigenesis assays, identifying c-Cbl/Cbl-b and ubiquitination as important negative regulators for this receptor (Peschard et al., 2001 (Peschard et al., , 2004 Abella et al., 2005) . This suggested that the inability to be targeted to the lysosomal degradative pathway and/or loss of Cblmediated ubiquitination may contribute to the oncogenic deregulation of Tpr-Met.
RTKs are frequently activated in human tumors following chromosomal translocation. In general, this fuses a protein dimerization domain with the cytosolic kinase domain of the receptor, resulting in constitutive receptor dimerization and activation (Lamorte and Park, 2001) . Over 25 RTK-derived fusion proteins have been identified in human tumors. In each case, the N-terminal signal peptide, necessary for protein targeting to the plasma membrane, is deleted in the rearranged kinase. With the exception of FIG-ROS, where studied, these proteins are cytosolic (Lamorte and Park, 2001 ).
Localization to the cytosol would preclude their entry into the endocytic pathway and hence, their lysosomal targeting and degradation. We predict that RTK-derived fusion proteins are more stable than their cognate receptors and that this feature contributes to their oncogenic activity. Here, we formally test this hypothesis using Tpr-Met as a model.
Results
The Cbl TKB-binding site is required for Cbl-mediated ubiquitination of Tpr-Met The Tpr-Met oncoprotein was used as a model to address whether the exclusion from endosomal-lysosomal degradative pathways of RTK-derived oncoproteins generated following chromosomal translocation, contributes to their transforming activity. Recruitment of cCbl and ubiquitination of the Met RTK requires Y1003 in the juxtamembrane domain of Met (Peschard et al., 2001 (Peschard et al., , 2004 . To examine a requirement for Cbl recruitment, we reintroduced the juxtamembrane domain from the Met receptor containing the Cbl TKB-binding site (Y1003) into Tpr-Met, (Tpr-Met-Juxta Y1003), as well as a mutant that fails to recruit the Cbl-TKB domain (Tpr-Met-Juxta Y1003F) (Figure 1 ). To study the importance of plasma membrane localization, TprMet and Tpr-Met-Juxta constructs were targeted to the plasma membrane by fusion to the interleukin 2-a leader sequence and transmembrane domain (Tac) (Naslavsky et al., 2003;  Figure 1 ).
Following transient transfections in human embryonic kidney 293 (HEK293) cells, all Tpr-Met proteins were expressed and showed similar levels of tyrosine phosphorylation, demonstrating that sequences added did not interfere with protein synthesis or activity (Figure 2a Membrane localization and ubiquitination decrease Tpr-Met protein stability To establish if subcellular localization and/or ubiquitination affect protein stability, we performed pulse-chase analyses. Cytoplasmic Tpr-Met (TM), and Tpr-Met containing the juxtamembrane domain (TMJ), show similar half-lives of approximately 9 h (Figure 5a ). Hence, presence of the Cbl TKB-binding site and ubiquitination of the Tpr-Met juxtamembrane-containing variant does not affect the stability of proteins localized in the cytoplasm. In contrast, membranelocalized Tac-Tpr-Met proteins containing the juxtamembrane domain and Y1003 residue, are more rapidly degraded (6-h half-life), than Tac-Tpr-Met proteins that lack the juxtamembrane domain or the Cbl TKB-binding site (Y1003F) (12-h half-life) ( Figure 5b ). This demonstrates that membrane localization is insufficient to target Tpr-Met for rapid degradation and that ubiquitination association with Cbl proteins are essential for rapid degradation of Tpr-Met.
The transforming activity of plasma membrane-targeted Tpr-Met proteins is suppressed by Cbl To examine the consequence of Cbl-induced ubiquitination versus escape from endosomal degradative pathways on Tpr-Met transforming activity, we performed soft agar assays using Rat1 fibroblasts expressing cytoplasmic and membrane-targeted Tpr-Met variants, with or without Cbl overexpression. Cbl expression had no effect on the colony-forming activity of cells expressing the cytoplasmic Tpr-Met or Tpr-Met-Juxta proteins (Figure 6a ). In contrast, coexpression with Cbl significantly suppresses the colony-forming ability of cells expressing the Tpr-Met variant containing the juxtamembrane Y1003 residue (Tac-Tpr-Met-Juxta Y1003, Figure 6b ) consistent with the reduced half-life of this variant in the presence of Cbl (Figure 5b) .
To examine the importance of ubiquitination and subcellular localization in promoting the transforming potential of Tpr-Met in vivo, the stable Rat1 cell populations were injected subcutaneously into nude mice. Tumor formation of all cell populations was observed as early as 5 days post-injection and initial measurements were comparable (Figure 7 ). Tumor growth following injection of cells coexpressing TacTpr-Met or Tac-Tpr-Met-Juxta Y1003F and Cbl was rapid, and skin ulceration was observed earlier than with mice injected with Tac-Tpr-Met-Juxta Y1003. However, as time progressed, tumors induced by cells coexpressing Cbl and the plasma membrane-targeted Tac-Tpr-Met-Juxta Y1003, showed reduced growth to 50% that of Tac-Tpr-Met with Cbl (Figure 7a ), even though the cells selected for injection expressed high levels of Tac-Tpr-Met-Juxta Y1003 (Figure 7b ).
Discussion
Receptor endocytosis, and subsequent degradation in the lysosomes, acts as an important mechanism that terminates receptor signaling following ligand activation (Katzmann et al., 2002) . A large family of oncogenic RTKs are activated in human tumors following chromosomal rearrangement. These proteins are no Additional constructs were targeted to the plasma membrane using the leader sequence, extracellular and transmembrane domains (272 aa) of the interleukin 2-a subunit (Tac). TKB, tyrosine-kinase binding.
Exclusion of Tpr-Met from endocytic degradation HHL Mak et al longer associated with the plasma membrane and are localized to the cytoplasm. In general, they are constitutively dimerized following fusion of the kinase domain with a protein-protein dimerization domain, and this was considered sufficient for their oncogenic activation (Rodrigues and Park, 1993) . In this study, we provide evidence that in addition to constitutive dimerization, the oncogenic activity of the Met RTKderived oncoprotein, Tpr-Met, is dependent on its ability to escape normal downregulatory mechanisms involving receptor endocytosis. Our findings provide a paradigm for the large family of RTK-derived oncoproteins activated in human cancers following chromosomal translocation. We show that membrane targeting is essential for Tpr-Met to enter the endocytic pathway and for its localization to EEA1-positive endosomes (Figure 4) . However, once engaged with the endocytic pathway, this is insufficient for efficient degradation, and a decrease in transforming efficiency of Tpr-Met proteins is dependent on both membrane targeting and the ability to engage with the Cbl ubiquitin ligase (Figure 6 ).
Ubiquitination plays an important role for the recruitment and trafficking of plasma membrane receptors 
Exclusion of Tpr-Met from endocytic degradation HHL Mak et al
within endocytic compartments and targeting of activated receptors for lysosomal degradation (Katzmann et al., 2002) . The ubiquitin moieties attached to the receptors are thought to be recognized by endocytic proteins that contain ubiquitin-binding modules, promoting both trafficking of the receptors and their inclusion into MVBs, leading to their lysosomal degradation (Katzmann et al., 2002) . We have shown that chromosomal translocation results in the deletion of the Cbl TKB-binding site on Tpr-Met and, as a consequence, Tpr-Met is not ubiquitinated (Peschard et al., 2001) . Although ubiquitination of this RTKderived oncoprotein can be restored upon addition of the juxtamembrane domain that contains the Y1003 residue (c-Cbl TKB-binding site; Figure 3 ), this does not alter its transforming activity ( Figure 7 ) and protein stability ( Figure 5 ), even when coexpressed with Cbl ubiquitin ligases. Hence, ubiquitination of cytosolic Tpr-Met is insufficient to promote enhanced degradation of this protein.
Since several RTKs appear to be monoubiquitinated and polyubiquitinated (Haglund et al., 2003; Mosesson et al., 2003; Carter et al., 2004; Huang et al., 2006) , Cbl-mediated ubiquitination of cytosolic RTKs activated following chromosomal translocation would not be predicted to target these proteins for proteasomal degradation, since the latter recognizes K48-linked chains of at least four ubiquitin residues (Thrower et al., 2000) . Reinsertion of the Met juxtamembrane domain into Tpr-Met has been proposed to be sufficient to decrease the transforming activity of this protein, which is contradictory to our data (Vigna et al., 1999) . This may reflect differences in the constructs generated, since the orientation of the Tpr dimerization domain with respect to the kinase domain can affect the efficiency of dimerization and catalytic activity of the enzyme (Rodrigues and Park, 1993) . Importantly, all of our constructs exhibited similar levels of autophosphorylation and phosphorylation of target proteins (Figures 2  and 3 ). Since the stability and transforming activity of a Tac Tpr-Met Juxta Y1003F Figure 4 Plasma membrane targeting of Tpr-Met promotes its entry into the endocytic pathway. Cos7 cells seeded on coverslips were transiently transfected with expression vectors encoding cytosolic and membrane-targeted Tpr-Met variants. Coverslips were fixed with 4% paraformaldehyde, stained with phospho-Met (Red) and EEA1 (Green) antibodies. Confocal images were taken with Â 100 objective and 1 Â zoom. Bar ¼ 10 um. EEA, early endosomal antigen.
Exclusion of Tpr-Met from endocytic degradation HHL Mak et al cytosolic Tpr-Met protein is unaffected by Cbl recruitment and ubiquitination (Figure 6 ), our data support that deletion of the extracellular domain of RTKs, which occurs following chromosomal rearrangement, is the key event that uncouples RTKs from normal degradative endocytic pathways. Once cytosolic, these RTK-derived oncoproteins are not targeted for degradation following ubiquitination by Cbl. This is distinct from transmembrane RTKs such as the Met receptor that engage the endocytic pathway, where loss of Cbl binding and ubiquitination is required to uncouple these proteins from degradation (Peschard and Park, 2003) . In agreement with this, Tpr-Met displays a half-life of approximately 9 h (Figure 5a ), while the half-life of an activated Met receptor is 60 min (Abella et al., 2005) .
More than 25 different RTK-derived oncoproteins have been generated following chromosomal translocation in human tumors (Lamorte and Park, 2001) . With one exception, all of these proteins are no longer associated with the plasma membrane and would not engage with the endocytic degradative pathway. Although engagement with the endocytic pathway and ubiquitination is not sufficient to suppress transformation by Tac-Tpr-Met-Juxta Y1003, this results in a significant decrease in anchorage-independent growth (Figure 6 ). Since the majority of these RTK-derived oncoproteins are constitutively activated, their ability to escape normal degradative pathways generates potent transforming genes.
In summary, we present a general mechanism for attenuation of RTK degradation through formation of RTK oncogenic variants that lack receptor extracellular domains, which leads to failure to enter the endocytic degradative pathway. Targeting of one of these proteins, Tpr-Met, to the plasma membrane engages this protein within the endocytic pathway, where its transforming activity is now attenuated by regulators of RTK degradation such as ubiquitination. Further progress in understanding the molecular basis for RTK degradation in human cancer will allow us to develop better strategies to target them efficiently.
Materials and methods

Cell culture, transfection
All cell lines were maintained in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum. HEK293 cells were transfected using Lipofectamine Plus reagent (Invitrogen, Carlsbad, CA, USA) and Cos7 cells with FuGene6 (Roche, Indianapolis, IN, USA). Stable transfections were performed using FuGene6 transfection reagent (Roche).
Immunoprecipitation and western blotting HEK293 cells were lysed 48 h post-transfection with 1% Triton lysis buffer (50 mmol/l 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (pH 7.5), 150 mmol/l NaCl, 2 mmol/l ethylene glycol tetraacetic acid, 1.5 mmol/l MgCl 2 , 1 mmol/l phenylmethylsulfonyl fluoride (PMSF), 1 mmol/l NaV, 50 mmol/l NaF, 10 mg/ml aprotinin and 10 mg/ml leupeptin). Cos7 cells were lysed with radioimmunoprecipitation (RIPA) buffer (0.1% sodium dodecyl sulfate (SDS), 25 mmol/l Tris (pH 8.0), 50 mmol/l NaCl, 0.5% NP-40, 0.5% NaDOC, 1 mmol/l PMSF, 1 mmol/l NaV, 10 mg/ml aprotinin and 10 mg/ml leupeptin). Antibodies were incubated with equal amounts of protein for 1 h at 41C with rotation. Proteins collected with Protein A/Protein G Sepharose were washed with RIPA buffer, subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membrane (Amersham Biosciences, Piscataway, NJ, USA). Membranes were blocked with 5% bovine serum albumin (BSA) in Tris-Buffered Saline Tween-20 (10 mmol/l Tris (pH 8.0), 150 mmol/l NaCl, 2.5 mmol/l ethylenediamine tetraacetic acid, 0.1% Tween-20). Immunoreactive bands were visualized by enhanced chemiluminescence (Amersham Biosciences). S-labeled cysteine and methionine for 2 h and then chased with complete medium for the indicated times. Cell lysates were pre-cleared with Protein A sepharose and later subjected to immunoprecipitation with Met antibodies. Samples were resolved using SDS-PAGE, dried and was exposed to a phosphoimager screen for analysis. SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
Antibodies and reagents
CA, USA), anti-c-Cbl (sc-170), anti-ubiquitin (P4D1) from Santa Cruz Biotechnology (Santa Cruz, CA, USA), antiphosho-Met (pY1234/35) from Cell Signaling Technology (Danvers, MA, USA) and anti-EEA1 antibody from BD Biosciences (Mississauga, ON, Canada).
Plasmid construction
For cytoplasmic Tpr-Met variants, the Tpr domain was subcloned into the pXM mammalian expression vector using XhoI and NotI sites using primers: forward 5 0 -TCATCTCGAG CGGGGCGGTGAGGTG-3 0 and reverse 5 0 -CTCAAGAAC TTGAATACTTAACAGCGGCCGCTACGTGAGTTCTTG AACT-TATGAATTGTCGCCGGCGATGCA-3 0 . Vectors containing Met wt and Y1003F cDNAs were used to amplify the cytoplasmic domain of Met using 5 0 -TAGCAGCGGCCGCA GATCTGGGCAGTGAATTAGTTCGCTACG-3 0 forward primer and 5 0 -CTGATGCGGCCGCGCATTGGTCCCTG GCCTG-3 0 reverse primer. NotI fragments were ligated into the pXM vector containing Tpr. The pBlueScript II SK ( þ )-TTC construct containing the Tac transmembrane domain was a kind gift from Dr Andre Veillette. The Tac fragment was amplified from the pBSK-TTC vector by using the T7 universal primer as the forward primer and reverse primer 5 0 -CTCAGGAATTCTCTCCGCTGCCAGGTGAGCCCAC-3 0 . Tpr-Met fragments were amplified from the pXM vector by using 5 0 -CCTGTAGAATTCGGCGGCGGCTCCGGAGGC GGTATGGCGGCGGTGTTGCAGCAAGTC-3 0 forward primer and 5 0 -CCTGACCCGGGGTGTGGACTGTTGCTT TGACATAG-3 0 reverse primer. Tac and Tpr-Met fragments were subcloned into pXM using XhoI/EcoR1 and EcoRI/ XmaI, respectively. Zeiss, Mississauga, ON, USA) with 100 Â objective and 1 Â zoom. Images were analysed with LSM 5 image browser (Carl Zeiss).
Confocal immunofluorescence microscopy
Soft agar assay
Rat1 cells (3.3 Â 10 4 ) stably expressing Tpr-Met variants, with or without Cbl, were seeded into 0.3% soft agar on top of a 0.6% agar layer in 60-mm plates. Cells were fed every 5-7 days by adding more top layer. Pictures were taken using the Axiovert Microscope with 2.5 Â objective and phase contrast setting. Colonies were counted after 21 days.
Metabolic labeling
At 24 h post transfection, HEK293 cells were incubated with cysteine-and methionine-free medium for 1 h, after which cells were incubated with complete media containing 0.1 mCi of 35 S-labeled methionine (Perkin Elmer, Waltham, MA, USA) for 2 h. Cells were washed and maintained in complete media for various time points. Cells were lysed with RIPA buffer, and lysates were pre-cleared with Protein A beads before immunoprecipitation. Intensity of the radioactive bands was analysed with Typhoon 8600 Phosphoimager (Amersham Biosciences).
In vivo tumorigenic assays Rat1 cells (5 Â 10 5 ) were injected subcutaneously in nude mice. Tumor progression was analysed by collecting data points every 2 days. At excision, tumors were frozen, grounded in liquid nitrogen and lysed in 1% Triton lysis buffer. Protein samples were resolved by SDS-PAGE and expression of the membrane-targeted Tpr-Met variants were analysed by immunoblotting with Met antibodies. 
